Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer

Next Previous
X
Search
Trial Profile

A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary)
  • Indications Early breast cancer; Male breast cancer
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms NeoEribulin; SOLTI NEOERIBULIN

    • Most Recent Events

    • 12 Dec 2015 Results of sub-group analysis (n=92) presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 02 Dec 2015 Results will be presented at the San Antonio Breast Cancer Symposium (SABCS), as per Eisai Co Ltd media release.
    • 06 Aug 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top